eujobs.coEU jobs in brussels
Post a JobHeadhunter

F. Hoffmann-La Roche Ltd

Acronym: Roche

General Information

Identification Code: 18940431725-51
Website: [object Object]
Entity Form: Corporation
Registration Category: Companies & groups
Registration Date: 5/20/2009
Last Update: 3/16/2024
EP Accredited Number: 1

Mission & Interests

Goals: Roche is a pioneer in pharmaceuticals and diagnostics making it a leader in personalised healthcare to advance science. Roche is the world’s largest biotech company, as well as the global leader in in-vitro and tissue-based cancer diagnostics. Since 1896, Roche searches for better ways to prevent, diagnose, and treat diseases and improves patient access to innovation. More than 30 medicines developed by Roche are included in the WHO Model Lists of Essential Medicines. For the 15th consecutive year, Roche was ranked one of the most sustainable companies by the Dow Jones Sustainability Indices. Roche employs over 103,000 people in over 100 countries. In 2023, Roche invested CHF 13.2 billion in R&D and posted sales of CHF 58.7 billion. Genentech, Flatiron Health, and Spark Therapeutics, all based in the US, are wholly owned members of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.
Interests Represented: Promotes their own interests or the collective interests of their members
Interests:
  • Budget
  • Business and industry
  • Climate action
  • Competition
  • Consumers
  • Digital economy and society
  • Economy, finance and the euro
  • Environment
  • External relations
  • Institutional affairs
  • International co-operation and development
  • Justice and fundamental rights
  • Public health
  • Research and innovation
  • Single market
  • Trade
Levels of Interest:
  • global

Activities

Main EU Legislative Proposals: Our objective is to improve patient safety and strengthen disease prevention in Europe, to provide coverage and reimbursement that reward innovation, and to increase Europe's competitiveness as a location for Research and Development investment. Our interactions with EU Institutions relate to the legislation and implementation of EU regulation at national level, e.g. Access to Medicines, EU Pharmaceutical Strategy, Incentives, Health Technology Assessment, In-Vitro Diagnostic / Medical Devices Regulations, General Data Protection Regulation, Shaping Europe’s Digital Strategy, Horizon Europe, Pharmaceuticals in the Environment, Shortages, Orphan Medicinal Products / Pediatric Regulations, European Green Deal, Cross-border Healthcare, European Health Union. Our expertise and knowledge enables us to contribute convincing arguments on policy topics that are of high priority to us, such as: How to provide patients with timely and safe access to medicines and diagnostics? How to create a culture which fosters innovation, e.g. by granting intellectual property (IP) protection? How to get a fair value for innovative products, devices and services? How to develop innovative diabetes technologies and services for patients? How to use innovative approaches to personalised healthcare by making use of big data while protecting data privacy? Consequently, we provide input to EU Institutions’ open consultations and participate in events sponsored by EU Institutions.
Communication Activities: We work actively on communication activities for better health care and access to patients, for instance via the Transforming Breast Cancer Together Initiative (https://www.tbct.eu/). We also advocate for regulatory reforms, such as the Six Bold Actions (https://www.roche.com/stories/roche-in-europe-hub). To this end, we communicate our proposals through publications, social media campaigns, events, or further types of activities. We also contribute to communication activities organized by associations such as the European Federation of Pharmaceutical Industries and Associations (EFPIA), MedTech Europe, the European Brain Council (EBC), the European Cancer Organisation (ECO), the European Patient’s Forum (EPF), the European Organisation for Rare Diseases (EURORDIS), and DigitalEurope.
Inter-institutional or Unofficial Groupings: N/A

Head Office

Address: Grenzacherstrasse 124
Post Code: 4070
City: Basel
Country: SWITZERLAND
Phone: [object Object]

EU Office

Address: Rue Dante 75
Post Code: 1070
City: Brussels
Country: BELGIUM
Phone: [object Object]

Financial Data

New Organisation: false
Closed Year: [object Object]
Current Year: [object Object]
Complementary Information: Roche's entries have been made in line with the greatest possible transparency and are periodically being updated as required. The estimates for this update have been done following the Transparency Register Guidelines for the 2021 Interinstitutional Agreement, and are consistent with the guidance provided by the European Federation of Pharmaceutical Industries and Associations (EFPIA).

Membership Information

Members10 Percent: 12
Members25 Percent: 5
Members50 Percent: 3
Members75 Percent: 0
Members: 21
Members F T E: 4.949999809265137
Info Members: Due to the complexity and highly technical nature of legislations on pharmaceuticals and diagnostics, Roche's approach to EU-related activities is decentralised and aims to mobilise subject-matter experts at the right time for the right issue. This division of tasks takes place based on specific functional expertise. Most experts, mainly located in Roche's headquarters in Basel, Switzerland, only spend a limited amount of their working time on EU-related activities. One person is fully dedicated to EU affairs and works in Brussels.

Structure

Structure Type: Structure
Is Member Of: Genentech, Flatiron Health, and Spark Therapeutics are wholly owned member of the Roche Group. According to the Transparency Register Guidelines for the 2021 Interinstitutional Agreement, the information published in the present registration also includes their activities.
Organisation Members: Roche is a member of the European Federation of Pharmaceutical Industries and Associations EFPIA, MedTech Europe, DigitalEurope, and of national pharmaceutical and diagnostics associations. In addition, Roche is a partner of the European Brain Council EBC, the European Cancer Organisation ECO, IMI’s European Patients' Academy on Therapeutic Innovation EUPATI, the European Organisation for Rare Diseases EURORDIS, the European Round Table for Industry ERT, European Patient Forum EPF, the Project Alzheimers Value Europe (PAVE), EUCOPE, and the European Policy Centre.